28.2 C
Vientiane
Sunday, October 12, 2025
spot_img
Home Blog Page 1385

PayPal’s Xoom partners with Tenpay Global to offer cross-border remittances to Weixin

New collaboration enables convenient and secure remittances to Weixin Pay users in China

SINGAPORE, April 9, 2025 /PRNewswire/ — Starting today, Weixin Pay users can now receive cross-border transfers from Xoom, a PayPal service and a pioneer in digital remittances. This new partnership between Tenpay Global, Tencent’s cross-border payment platform, and Xoom allows Weixin Pay users to receive money directly into their Weixin Pay Wallet Balance or bank accounts linked to Weixin Pay through Xoom or PayPal’s mobile app and website.


Xoom and PayPal users in United States, Canada and Europe can now access reliable and affordable cross-border money transfers to their own or family members’ Weixin Pay accounts, with additional countries to come in the future. Weixin Pay users can receive the funds frictionlessly, typically in as fast as a few minutes, for flexible use within the Weixin app for transfers, top-ups and shopping.

“Xoom has long been known as a fast, easy, inexpensive way to send money to friends and family across borders – and now, being able to send funds to Weixin Pay users from the US, Canada and Europe, we’re continuing to connect users wherever they might be and for what they might need funds for,” said Paul Bances, Vice President of Market Development for Xoom.

“This partnership reaffirms Tenpay Global’s commitment to not only bridging the Weixin ecosystem with the global markets but also enhancing user value through streamlined and secure cross-border remittances. By addressing everyday needs—from family support to daily expenses—we aim to create meaningful value in our users’ lives beyond mere transactions,” said Wenhui Yang, CEO of Tenpay Global (Singapore).

The service is now live and available through the Xoom and PayPal mobile app. Users may also visit Xoom.com or PayPal.com to start the remittance experience.

Xoom or PayPal users in the United States, Canada, and Europe can easily send remittances to Weixin in just a few simple steps.
Xoom or PayPal users in the United States, Canada, and Europe can easily send remittances to Weixin in just a few simple steps.

About Xoom

A pioneer in digital remittances, Xoom is a fast and easy way to send money, pay bills and reload phones for friends and family in approximately 160 countries globally. With Xoom, customers can access a fast and reliable way to send money, by simply downloading the Xoom or PayPal mobile app, or visiting Xoom.com or PayPal.com.

About Tenpay Global

Tenpay Global, the cross-border payment platform of Tencent, is the gateway to seamless cross-border payment solutions for businesses and individuals. Tenpay Global offers scenario-based services for different customer groups, including cross-border consumption, cross-border remittances, and cross-border commerce scenarios. Together with global partners, Tenpay Global is committed to bridging the world’s payment networks with Weixin’s ecosystem in China.

Siemens Healthineers and Singapore General Hospital Announce Strategic Partnership to Advance Healthcare Innovation

  • Five-year strategic partnership to improve patient care
  • Focus on developing new technologies, improving diagnostics and treatment protocols, providing training and knowledge sharing.

SINGAPORE, April 8, 2025 /PRNewswire/ — Siemens Healthineers and Singapore General Hospital (SGH) have recently signed a Memorandum of Understanding (MOU) to establish a five-year strategic partnership to advance healthcare solutions and support SGH in medical innovation. Working together, the two organizations aim to strengthen Singapore’s healthcare ecosystem by driving continuous learning, innovation, and excellence in patient care.

A/Prof Andrew Tan of SGH, Dr Jochen Schimtz of Siemens Healthineers, A/Prof Ruban Poopalalingam of SGH, and Enno Nehrbass of Siemens Healthineers signed the MOU pledge in Siemens Healthineers HQ Erlangen, Germany.
A/Prof Andrew Tan of SGH, Dr Jochen Schimtz of Siemens Healthineers, A/Prof Ruban Poopalalingam of SGH, and Enno Nehrbass of Siemens Healthineers signed the MOU pledge in Siemens Healthineers HQ Erlangen, Germany.

The MOU, signed at the Siemens Healthineers headquarters in Erlangen, Germany,  focuses on improving patient care by developing new technologies, clinical solutions, and data-driven approaches to enhance diagnostics and treatment protocols. The collaboration emphasizes hands-on training, workshops, and knowledge-sharing initiatives to build expertise and capacity, while also laying the foundation for future advancements in AI-driven diagnostics, digital health solutions, and sustainability initiatives.

“Singapore General Hospital has always been our valued partner in diagnostic imaging, and this partnership marks a significant step forward in driving medical innovation and enhancing patient outcomes,” said Ms Siow Ai Li, Managing Director, Siemens Healthineers Singapore and Malaysia. “Collaboration is key to advancing healthcare. By co-developing new clinical solutions and leveraging our expertise, we are committed to supporting SGH and the broader Singapore healthcare landscape in pioneering future-ready innovations.”

This strategic partnership is built on these key pillars:

  • Clinical Research and Collaboration – Siemens Healthineers and SGH aim to develop new technologies, clinical solutions and data-driven approaches to enhance diagnostic and treatment capabilities and protocols. This collaboration aims to foster innovation and improve patient care through joint research initiatives and clinical trials.
  • Education and Training – Siemens Healthineers is committed to supporting SGH with the latest knowledge and skills. Through partnering with SGH for hands-on training, workshops, and knowledge-sharing initiatives, this partnership will build expertise and capacity to deliver better patient care.
  • Future-ready Healthcare: The partnership will lay the foundation for future collaboration in areas such as AI-driven diagnostics, digital health solutions, and sustainability initiatives. By leveraging advanced technologies, SGH and Siemens Healthineers aim to stay at the forefront of medical innovation.

This collaboration creates valuable opportunities for mutual knowledge exchange between Siemens Healthineers and SGH. By sharing best practices and expertise, both parties can co-develop innovative solutions that address evolving healthcare challenges. Siemens Healthiners aims to support SGH’s medical professionals with our innovative services and insights, while SGH’s clinical expertise and real-world experience will help refine and advance cutting-edge medical technologies.

This partnership marks another step towards future-ready healthcare, opening up exciting possibilities in diagnostic imaging and radiological sciences. We look forward to working closely with Siemens Healthineers to pioneer new approaches in diagnostics and treatment, driven by AI and data, while building valuable expertise among our healthcare professionals through knowledge exchange and training initiatives,” said Associate Professor Andrew Tan, Chairman, Division of Radiological Sciences, SGH.

“At Siemens Healthineers, we are convinced that strategic partnerships are pivotal to advancing healthcare for everyone,” said Dr Jochen Schmitz, CFO Siemens Healthineers. “It was a pleasure to recently welcome the team from Singapore General Hospital in Erlangen and engage in a meaningful exchange of ideas on co-developing solutions that benefit both patients and healthcare professionals. We look forward to continuing our collaboration based on the pillars of this memorandum of understanding.”

The two organizations aim to determine the next areas of focus for various workstreams, with a steering committee set to oversee and guide activities under this strategic partnership and MOU.

This press release and a press picture is available at

https://www.siemens-healthineers.com/en-sg/press-room/press-releases-sg/sgh-signs-mou-with-shs-5-years-strategic-partnership 

The product/features mentioned in this press release is/are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens organization for further details. The product and features mentioned in this press release are meant for healthcare professionals only.

Contact for media enquiries, please get in touch with:

Siemens Healthineers
Jo’an Chng
Head of Marketing, Sales Operations and Communications
Phone: +65 8328 1015; E-mail: jo-an.chng@siemens-healthineers.com 

Singapore General Hospital
Candice Lee
Communications, Singapore General Hospital
Email: candice.lee.l.f@sgh.com.sg 

Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2024, which ended on September 30, 2024, Siemens Healthineers had approximately 72,000 employees worldwide and generated revenue of around €22.4 billion. Further information is available at www.siemens-healthineers.com.

Singapore General Hospital, established in 1821, is the largest acute tertiary hospital in Singapore and ranked among the world’s best. It provides the most comprehensive patient-centred care with over 50 clinical specialties on its campus. As an Academic Medical Centre, it takes pride in training healthcare professionals and conducting cutting edge research to meet evolving needs of the nation as well as the region. Driven by a strong sense of purpose, SGH is committed to give of its best to heal and bring hope, as it has for over 200 years. Clinical research is an integral part of SGH’s institutional practice and is actively carried out by clinicians and scientists from medical, nursing and allied health departments. The hospital leverages on its multi-disciplinary capabilities, depth of specialization, a large patient base and its research affiliations with renowned centres locally and globally. A not-for-profit institution, SGH is wholly owned by the government of Singapore and the flagship hospital of the public healthcare system. SGH is a member of the SingHealth cluster of healthcare institutions. Further information is available at www.sgh.com.sg.

 

The Sennheiser MKH 416 shotgun microphone celebrates its golden jubilee this year

Enjoy an anniversary discount on the all-time classic in April

SINGAPORE, April 9, 2025 /PRNewswire/ — One of Sennheiser’s most revered microphones, the MKH 416 P48 shotgun microphone, celebrates its golden jubilee this year! For 50 years, the MKH 416 has accompanied broadcasters, filmmakers, voice-over artists, and content creators; it has been used in studios and in the field. Mounted onto a boom pole, a stand or a camera, its job has been to stay outside the camera angle while gracefully capturing sound with clarity and impact. To celebrate its golden jubilee, this classic mic is offered at an anniversary discount at Alan Photo, Cathay Photo, City Music, Hung Brothers and Wailian Electronics. 


Time travelling to the 1970s

The name of Manfred Hibbing is firmly linked with this milestone product. When the young engineer joined Sennheiser, his first task was to design the MKH 416 P48 on the basis of the MKH 415 T. The MKH 416 was to be Sennheiser’s first phantom-powered (P48) shotgun microphone, while all previous models were AB-powered. In those days, AB powering was preferred in broadcast situations because of its resistance to ripple voltages, but phantom powering had become established in the studio.

50 years old but always up to date

Hibbing’s involvement was a stroke of luck for the MKH 416 RF condenser microphone, as he possessed ample expertise both in electroacoustics and in RF technology. In an interview in 2023, he said that optimising the interaction between the electroacoustic transducer and the electronic circuit had been his favourite task in designing the 416.

The long lifespan of the MKH 416 P48 fills the engineer with pride: “During all this time, the design of the MKH 416 was only revised in two instances: one was to make it suitable for SMD mounting, and the other to update it for a more advanced transducer technology.”

Manfred Hibbing with the MKH 416. The photo was taken in 2023
Manfred Hibbing with the MKH 416. The photo was taken in 2023

A standard in the studio and in the field – but why exactly?

One reason is that the MKH 416 operates on the RF condenser principle. In this context, RF (radio frequency) has nothing to do with wireless, but rather refers to the high-frequency voltage at the capsule and the associated electronics in the microphone. The huge advantage of this design is that it makes the condenser microphone resistant to humidity. Unlike “standard” condenser microphones, RF condenser models can be used outdoors, in hot and humid or cold and misty weather. MKH microphones have reliably recorded audio in a wide variety of challenging locations, from deserts, to the Arctic, to rain forests.

RF condenser microphone used in outdoor broadcasting
RF condenser microphone used in outdoor broadcasting

Another reason for the success of the MKH 416 is in its excellent directivity, which is the result of the acoustic interference principle on which it operates. The actual microphone capsule is combined with a so-called interference tube in front of it. This tube has regularly arranged slots, which are covered with fabric that has a certain acoustic impedance, and prevents reflections and standing waves inside the tube. If sound arrives directly from the front, the interference tube has no effect at all. But when sound enters the tube from the sides, it passes through different holes. This results in different path lengths to the transducer and thus different time delays. Depending on the angle of sound incidence, the sound components more or less cancel each other out. This effect increases at higher frequencies: Here, the microphone essentially picks up the sound coming from the front. This is particularly important for speech intelligibility as the decisive speech formants are recorded with less lateral interference at high frequencies than with standard microphones.

The longer the shotgun, the more this interference principle extends to lower frequencies. Unfortunately, the longer length also makes the microphone more difficult to handle. The MKH 416 is certainly so popular because, despite its short length, it offers an effective directionality. How this particular length came about is its own story, and that takes us back to its predecessor, the MKH 415 T…

The hacksaw and the microphone

In 1970, the newly designed MKH 415 shotgun microphone was the pride and joy of the Sennheiser development engineers. It was less sensitive to wind and pop noise, had greater resistance to handling noise, and excellent directivity. With the new microphone in his briefcase, an enthusiastic Dr. Griese, technical manager at Sennheiser, went off to visit radio and TV broadcasters.  The customers showed a great deal of interest in the new shotgun microphone – but couldn’t resist picking at it. They complained that the shotgun effect was so strong that you had to keep moving the microphone to follow the speaker around.

Dr. Griese listened to the comments for a while and then asked for a hacksaw. “How much directivity would you like?” he asked the amazed observers. And without batting an eyelid he proceeded to saw off a section of the microphone tube. The customers were stunned. Dr. Griese then tried out the shortened microphone once again and, to everyone’s amazement, it was perfect! From then on, the MKH 415 – and thus also the MKH 416 which followed its design – were highly successful as the preferred microphone for vocalists, film teams and reporters, with the specialist media being equally impressed by the “unusually short length” (Funkschau) of the shotgun mic.

Conclusion

“The MKH 416 remains a star of our shotgun microphones, even though we have launched younger models long since,” concludes product manager Kai Lange. “It’s just great to have such a legend in the portfolio, a versatile, long-life, high-performance microphone. The MKH 416 is a mic where everything was perfect from the start.”

The high-resolution images accompanying this media release can be downloaded here.

 

Inditex supports Asian University for Women by funding the university education of 50 female textile industry workers in Bangladesh for five years

The beneficiaries of this new Inditex scholarship program, aimed at promoting professional development at the Asian University for Women, will be selected from the workers of Inditex’s partner suppliers in the country


ARTEIXO, SPAIN – Media OutReach Newswire – 9 April 2025 – Inditex and the Asian University for Women have launched a new scholarship program to support the academic training of female textile factory workers in Bangladesh. Inditex will allocate €3.75 million to fund this initiative, enabling 50 women to access pre-university and university education over the next five years, providing them with new opportunities for personal and professional growth.

Inditex will fund the university education of 50 female textile industry workers in Bangladesh for five years

Access to higher education for women remains a critical issue in Bangladesh, where female university enrollment is increasing at a slower rate than that of men. In this context, AUW is dedicated to empowering women from all backgrounds, equipping them with the skills to become more qualified professionals, leaders in their communities and workplaces, and advocates for economic and cultural development.

“At Inditex, we believe that empowering women through education is one of the most effective ways to drive lasting and meaningful change in these communities. Through this scholarship program, we are investing in the future of female workers—the backbone of our supply chain—by providing them with the tools to unlock new opportunities and foster progress within their communities,” said Inditex CEO Óscar García Maceiras.

“At a time when uncertainty in global affairs has reached a new height, the partnership between Inditex and the Asian University for Women reminds us of what really matters — the weakest in our society must get the opportunities to rise above the circumstances that circumscribe the possibilities in their life. As the first one in my family to enter university, I know how powerful higher education can be in opening doors that otherwise remain unimaginable. I commend Inditex for this far-reaching commitment that will help deepen AUW’s ability to identify talent where few others see them and nurture them so that they too can contribute in the making of a better future for themselves and the world”, Cherie Blair, Chancellor of the Asian University for Women.

Set to launch in the upcoming academic year, this initiative will enable 50 female textile workers in Bangladesh to cover their tuition, accommodation, and living expenses for five years. The selection process will begin in the coming weeks and will take place at Inditex’s supply chain factories in the country. As part of the process, AUW will conduct informational sessions, selection interviews, and admission tests at participating factories for all interested workers.

Hashtag: #AsianUniversityforWomen

The issuer is solely responsible for the content of this announcement.

Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis

YANTAI, China, April 9, 2025 /PRNewswire/ — On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®) in patients with generalized myasthenia gravis (gMG) were presented during the Late-Breaking Science Session at the American Academy of Neurology (AAN) Annual Meeting 2025 in San Diego, CA.

According to the presented data, among the participants in the Telitacicept 240 mg group, 98.1% of the patients demonstrated a ≥ 3-point reduction in Myasthenia Gravis Activities of Daily Living (MG-ADL) score and 87% of the patients demonstrated a ≥ 5-point reduction in Quantitative Myasthenia Gravis (QMG) score at Week 24. With the highest MG-ADL response rate among all drugs for gMG with phase 3 studies reported to date, Telitacicept will provide an important new treatment option gMG.

Telitacicept is a novel fusion protein targeting both BlyS and APRIL independently designed and developed by RemeGen Co.,Ltd. (“RemeGen”). The multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial was conducted in China (NCT05737160) and led by Professor Jian Yin of Beijing Hospital. A total of 114 gMG patients with baseline MG-ADL score ≥6 and QMG score ≥8 were enrolled in the study, with 57 patients in the Telitacicept 240 mg group and the placebo group respectively. The study consisted of a 24-week double-blind treatment stage and an open-label treatment stage. The presented results herein were from the double-blind treatment study.

The data showed that ‌Telitacicept‌ achieved ‌sustained and significant improvement‌ in clinical outcomes for patients with gMG, ‌with a favorable safety profile:

  • Telitacicept demonstrated significant improvements‌ in MG-ADL and QMG scores after 4 weeks’ treatment compared to placebo.
  • At Week 24, change in MG-ADL was -5.74 and -0.91 with Telitacicept and placebo group, respectively. 98.1% and 12.0% of Telitacicept and placebo group patients had ≥3-point reduction in MG-ADL, respectively. The MG-ADL scale quantifies the impact of MG symptoms on daily life quality, focusing on patients’ subjective experience and daily function. These data showed that patients treated with Telitacicept achieved ‌clinically meaningful improvement‌‌.
  • At Week 24, change in QMG was -8.66 and -2.27 with Telitacicept and placebo group, respectively. 87.0% and 16.0% of Telitacicept and placebo group patients had ≥ 5-point reduction in QMG, respectively. The QMG score assesses the strength and endurance of the whole body muscle group, focusing on objective measurement. These data demonstrated that patients treated with Telitacicept‌ achieved ‌clinically meaningful reductions in disease severity. There is a strong correlation between MG-ADL and QMG in evaluating treatment response, and the combination of MG-ADL and QMG can comprehensively reflect the disease severity.
  • Sustained improvement: MG-ADL and QMG scores continued to decline over time in the Telitacicept group, with peak improvement at the last reported observation, Week 24.
  • Telitacicept was well tolerated during the treatment, with an overall adverse event (AE) incidence similar to that in the placebo group and an incidence of infection-related AEs lower than that in the placebo group (45.6% vs. 59.6%).

The principal investigator Prof. Yin Jian of Beijing Hospital said “Telitacicept demonstrated rapid and significant clinical improvement in the phase 3 trial, and was well tolerated. Its dual-targeting mechanism not only inhibits abnormal B cells and plasma cells thoroughly and reduces the level of pathogenic antibodies, but also effectively slows down disease progression in the long term, and reduces steroid dosage as symptoms improve, providing a more precise, efficient, persistent, and safer option for gMG treatment.”

Dr. Jianmin Fang, CEO of RemeGen, said “The phase 3 data of Telitacicept for MG is clinically meaningful. There is a large unmet medical need in MG because the disease presents significant threat to patients’ health and life-span. This breakthrough means that we have an new, effective treatment for MG as Telitacicept can significantly improve patients’ symptoms and bring long term benefits to MG patients. We look forward to working with global experts and scholars to overcome more complex autoimmune diseases and benefit more patients.”

MG is an autoimmune disease caused by neuromuscular junction transmission disorders. It is characterized by fatigue and fluctuations in symptoms, long treatment cycles and high recurrence rate. More than 85% of patients develop to gMG within 24 months of onset. According to Frost & Sullivan report, there are about 1.2 million MG patients worldwide, including about 220,000 patients in China. At present, there is a great unmet medical demand.

The newly disclosed “best-in-class” data mark a breakthrough achievement of Chinese innovative drugs in the field of neuroimmunology. Currently, the BLA of Telitacicept for the treatment of gMG has been accepted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration, and it is expected to be approved in China in the second quarter of this year.

Meanwhile, RemeGen is advancing a global multicenter Phase 3 trial of Telitacicept for the treatment of gMG, aiming to validate the efficacy and safety of Telitacicept in a wider patient population, and to provide a superior treatment option for gMG patients worldwide.

Chula Partners with MIT LGO to Launch Chula-LGO A Master’s Program in Engineering and Business

Creating a New Generation of Leaders with Technical Knowledge and Business Management Skills 

BANGKOK, April 9, 2025 /PRNewswire/ — Chulalongkorn University, through its Faculty of Engineering and Chulalongkorn Business School (CBS), has announced a collaboration with the Massachusetts Institute of Technology’s Leaders for Global Operations (MIT LGO) program. This partnership was unveiled at the 31st Chula the Impact academic seminar, organized by Chulalongkorn University Communications Center. The new Chula-LGO program aims to cultivate leaders equipped with both technical expertise in engineering and business acumen, addressing the evolving demands of industries in the digital era and the global economy. 

Chula Partners with MIT LGO to Launch Chula-LGO: A Master’s Program in Engineering and Business
Chula Partners with MIT LGO to Launch Chula-LGO: A Master’s Program in Engineering and Business

The signing ceremony between Chulalongkorn University and MIT LGO featured remarks from Prof. Dr. Wilert Puriwat, President of Chulalongkorn University, who emphasized the significance of the program: 

“Chula-LGO is more than just another master’s program; it is a transformative step in advancing Thai education to meet international standards. Through our collaboration with MIT LGO, students will gain cutting-edge knowledge, engage with real-world industries, and be equipped to take on leadership roles in the global economy.”

Chula-LGO: An Integrated Program for the Future
Chula-LGO is a two-year master’s program offering an interdisciplinary learning experience. Students will earn a Master of Engineering degree from Chulalongkorn University and an MBA from Chulalongkorn Business School. The curriculum combines rigorous academic coursework with practical experience, including a two-week study period at MIT LGO and a six-month research and internship project within the industrial sector. This structure ensures that graduates are well-prepared to tackle real-world challenges.

Assoc. Prof. Dr. Witaya Wannasuphoprasit, Dean of the Faculty of Engineering, Chulalongkorn University, further elaborated on the program’s strengths and interdisciplinary approach:

“Engineering today is not just about designing and developing technology– it must also integrate effectively with business management and operations. Chula-LGO answers the needs of future industry leaders, providing deep skills in technical expertise, innovation, and management.” 

Assoc. Prof. Dr. Tartat Mokkhamakkul, Dean of the Chulalongkorn Business School, highlighted the business perspective: 

“Modern businesses rely on technology and efficient supply chain management to maintain a competitive edge. Chula-LGO develops strategic thinkers capable of making data-driven decisions using advanced technology. This is a key factor in creating a competitive advantage for organizations.”

Industry Support and Economic Impact
The Chula-LGO program has garnered support from leading industry organizations. Dr. Kobsak Pootrakool, Executive Vice President of Bangkok Bank Public Company Limited, discussed the role of the business sector in supporting this program:

“Today’s industries require professionals who possess both technical expertise and organizational management skills. The Chula-LGO program bridges the gap between academia and business, developing talent capable of competing in the global market and propelling Thailand’s economy forward.” 

“MIT LGO is excited to collaborate with Chulalongkorn University on this initiative. This partnership will not only enhance the curriculum but also foster joint research, faculty, researcher, and student exchanges, contributing to the advancement of Thailand’s industries to meet global standards.” 

Chula-LGO is poised to play a pivotal role in Thailand’s human resource development, especially as Digital Transformation, Artificial Intelligence, and Industry 4.0 technologies reshape the global landscape. The program aims to cultivate a network of leaders capable of steering organizations to success on the international stage.

About Chula-LGO
Chula-LGO is a collaborative program developed by the Faculty of Engineering and the Chulalongkorn Business School at Chulalongkorn University, in partnership with MIT Leaders for Global Operations (MIT LGO). The program’s mission is to produce leaders who can drive industries and businesses in the digital era through integrated education in engineering, technology, and business management. 

For more information on the program and admissions, visit the Faculty of Engineering or Chulalongkorn Business School websites: http://www.eng.chula.ac.th or http://www.cbs.chula.ac.th 

Read the full article at https://www.chula.ac.th/en/news/227346/

About Chulalongkorn University
Chulalongkorn University has made the world’s top 50 university list for employment outcomes, which reflects both the high employment rate and work ability of Chula graduates. The university is also listed as the best in Thailand for the 15th Consecutive Year (since 2009), according to the newly released QS World University Rankings 2024, putting Chula at 211th in the world, up from 244th last year.

Social Media:
Facebook: https://www.facebook.com/ChulalongkornUniversity
Youtube:
https://www.youtube.com/chulauniversity
Linkedin: https://www.linkedin.com/school/15101896/

 

Nippon Steel and TIER IV Collaborate to Automate Heavy-Duty Transporters at Nagoya Plant

TOKYO, April 9, 2025 /PRNewswire/ — Nippon Steel Corporation (Nippon Steel), Japan’s largest steelmaker and one of the world’s leading steel manufacturers, and TIER IV, Inc. (TIER IV), the pioneering force behind the world’s first open-source software for autonomous driving, are working together to automate steel transportation with heavy-duty autonomous vehicles, aiming to deploy the technology at the steelmaker’s Nagoya plant in fiscal 2025.

The companies have been collaborating to tackle challenges linked to labor shortages with autonomous driving technology since fiscal 2023. To optimize logistics and enhance plant safety, Nippon Steel is driving efforts to automate vehicles such as the specialized transporters that carry pallets loaded with steel plates.

TIER IV offers reference designs to streamline the development and deployment of autonomous driving systems. In this collaboration, reference designs for factory logistics are being customized to develop an autonomous driving system for steel transportation.

Nippon Steel and TIER IV are committed to tackling challenges such as labor shortages, pioneering innovations that will revolutionize plant efficiency and safety with autonomous driving technology.

About Nippon Steel

Nippon Steel is Japan’s largest and one of the world’s leading steel manufacturers, operating production bases in Japan and more than 15 countries worldwide. The Nippon Steel Group is engaged in four key business areas: steel manufacturing, engineering, chemicals & materials, and system solutions. The company’s management plan focuses on four pillars: “Reconstruction of Domestic Steel Business and Strengthening of Group Management,” “Global Strategy for Evolution and Expansion of Overseas Business,” “Challenges Toward Carbon Neutrality,” and “Promotion of Digital Transformation Strategy.” Aiming to become the world’s No.1 comprehensive steel manufacturer, Nippon Steel pursues the highest levels of technology and manufacturing excellence to contribute to society through superior products and services. For more details, please visit Nippon Steel’s website: https://www.nipponsteel.com/.

About TIER IV

TIER IV stands at the forefront of deep tech innovation, pioneering Autoware, the world’s first open-source software for autonomous driving Harnessing Autoware, we build scalable platforms and deliver comprehensive solutions across software development, vehicle manufacturing, and service operations. As a founding member of the Autoware Foundation, we are committed to reshaping the future of intelligent vehicles with open-source software, enabling individuals and organizations to thrive in the evolving field of autonomous driving.

Autoware is a registered trademark of The Autoware Foundation.

Media Contact
Nippon Steel
https://www.nipponsteel.com/contact/
TIER IV
pr@tier4.jp

SWISS REJU Ranks Number 1 in “Sunday More Beauty 100 Award”, Breaking Record with 8 Major Wins , Showcasing Commitment to Innovation

HONG KONG, April 9, 2025 /PRNewswire/ — Luxury beauty brand SWISS REJU is Hong Kong’s No.1 Best Body Slimming and Contouring Provider, according to Sunday More Beauty 100 Award Annual Rankings. This honour is particularly meaningful, as it is the 8th consecutive award won by the brand, after major recognitions from HK01, Cosmopolitan, JESSICA etc. The latest winning streak reflects a strong and consistent record of exceptional service and satisfactory body contouring outcomes SWISS REJU provides.

Each year, Sunday More’s Beauty 100 Award evaluates brands based on verified customer feedback, real expert panel evaluation, and a robust editorial review process. Earning a place on this competitive and prestigious list is a testament to the quality and efficacy of SWISS REJU’s signature body contouring treatment K-Lipolysis. More 100 Awards are presented across a wide selection of categories, from beauty products to slimming services, and only established brands with excellent reputation are eligible to compete.

“We are delighted to commence the year in such a positive manner, we are incredibly honored to be recognised in this prestigious award. Thank you Sunday More for rewarding us as the No.1 Best Body Contouring Treatment!” says the spokesperson of SWISS REJU.


SWISS REJU Ranks Number 1 in Sunday More Beauty 100 Award, Breaking Record with 8 Major Wins 

In a significant advancement for the industry, SWISS REJU is introducing BTL EXION, an innovative AI-driven medical platform developed by BTL Industries. This breakthrough technology is designed to enhance treatment for chronic conditions, with clinical studies indicating substantial improvements in levels of hyaluronic acid, collagen, and elastin. The integration of BTL EXION into SWISS REJU’s offerings represents a step forward in the application of artificial intelligence in aesthetic medicine.

SWISS REJU continues to expand its technological capabilities with additional cutting-edge solutions, including:

  • ATP Lipo X: A dual RF/Ultrasound platform aimed at enhancing cellular energy and promoting overall wellness.
  • Smartlux Laser: A laser technology recognized for its effectiveness in stimulating collagen production.
  • Yaman Queen Lift: An advanced energy platform designed for skin firming and facial contouring.

“We are honored to receive this recognition and remain committed to leveraging innovative technologies to enhance client experiences,” said a spokesperson for SWISS REJU. “Our focus on integrating advanced solutions reflects our dedication to improving outcomes in aesthetic treatments.”

For more information about SWISS REJU and its innovative offerings, please visit http://www.reju.hk